B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.

导出 OA

翻译打印收藏纠错

第一作者： Juan,Ma

第一单位： Department of Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.

作者： Juan,Ma ^[1] ; Pan,Ma ^[2] ; Chenghai,Zhao ^[3] ; Xin,Xue ^[4] ; Huamin,Han ^[5] ; Changzhen,Liu ^[6] ; Hua,Tao ^[5] ; Weigang,Xiu ^[1] ; Jia,Cai ^[1] ; Man,Zhang ^[1]

作者单位： Department of Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China. ^[1] Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. ^[2] Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, China. ^[3] Department of Immunology, China Basic Medical Theory of Chinese Medicine, Academy of Chinese Medical Sciences, Beijing, China. ^[4] CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. ^[5] Department of Molecular Biology, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China. ^[6] Chinese Medical Doctor Association of Lab Medicine, Beijing, China. ^[7]

关键词 B7-H3 bispecific antibody immunotherapy